7 stories mentioning VCYTUpdated 10d ago
Every FINWIRES story that references VCYT, newest first.
Marc Stapley, Director, Chief Executive Officer, on June 02, 2026, sold 138,051 shares in Veracyte (VCYT) for $6,919,585. Following the Form 4 filing with the SEC, Stapley has control over a total of 440,494 common shares of the company, with 440,494 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1384101/000153979626000015/xslF345X05/wk-form4_1780623504.xml
Veracyte (VCYT) said results from an independent Phase 3 trial show its Prosigna Breast Risk of Recurrence test can safely guide adjuvant chemotherapy decisions for patients with early-stage, ER-positive, HER2-negative breast cancer.The study, led by University College London, enrolled 4,429 patients and had a median follow-up of four years, Veracyte said Friday in a statement. Investigators reported that Prosigna provided Level 1A evidence, demonstrating the test can accurately predict chemotherapy benefit and support safe treatment de-escalation across high-risk groups.The results will be presented Saturday at the annual meeting of the American Society of Clinical Oncology.Price: $46.32, Change: $-1.67, Percent Change: -3.48%
Robert S Epstein, Director, on May 20, 2026, sold 10,000 shares in Veracyte (VCYT) for $440,129. Following the Form 4 filing with the SEC, Epstein has control over a total of 52,446 common shares of the company, with 52,446 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1384101/000125200426000002/xslF345X05/wk-form4_1779482346.xml
Veracyte (VCYT) said Friday its TrueMRD Monitoring Test received Medicare coverage for patients with muscle-invasive bladder cancer.The diagnostic tool is approved for tracking disease recurrence following treatment, and it detected disease return median of 131 days earlier than standard imaging during clinical studies, the company said.The product will be commercially available for healthcare providers to order beginning June 1, Veracyte said.Shares of the company were down 1.1% in Friday trading.Price: $38.27, Change: $-0.63, Percent Change: -1.62%
Veracyte (VCYT) has an average rating of overweight and mean price target of $47.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $37.50, Change: $+4.53, Percent Change: +13.74%
Veracyte (VCYT) reported Q1 non-GAAP net income late Tuesday of $0.52 per diluted share, up from $0.31 a year earlier.Analysts polled by FactSet expected $0.33.Revenue for the three months ended March 31 rose to $139.1 million from $114.5 million a year earlier.Analysts surveyed by FactSet expected $130.4 million.The company raised 2026 revenue guidance to $582 million to $592 million from $570 million to $582 million previously. Analysts surveyed by FactSet expect $580.4 million.Veracyte shares rose more than 12% in recent premarket activity Wednesday.Price: $37.00, Change: $+4.03, Percent Change: +12.22%
Veracyte (VCYT) has an average rating of overweight and mean price target of $47.83, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
